Plasma Cell Leukemia Clinical Trials

48 clinical trials for Plasma Cell Leukemia across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial — RECRUITING · PHASE2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances — RECRUITING · PHASE1
• The Norwegian Immunotherapy in Multiple Myeloma Study — RECRUITING
• Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level — RECRUITING · PHASE3
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant — RECRUITING · PHASE2
• IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia — RECRUITING · PHASE2
• Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry — RECRUITING
• European Myeloma Network (EMN) Sample Project — RECRUITING
• Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma — RECRUITING · PHASE2
• Registry for Adults With Plasma Cell Disorders (PCD's) — RECRUITING
• Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM — RECRUITING · PHASE1
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia — RECRUITING · PHASE2
• A Study of CT0596 in Plasma Cell Leukemia — RECRUITING · PHASE1
• Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research — RECRUITING · PHASE1
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — RECRUITING · PHASE1
• A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — RECRUITING · PHASE1
• To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL — RECRUITING · PHASE1
• A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH — RECRUITING
• A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia — NOT_YET_RECRUITING · PHASE2
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases — TERMINATED · NA
• High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia — ACTIVE_NOT_RECRUITING · NA
• Expanded Access to Venetoclax — OTHER
• IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma — WITHDRAWN · PHASE1
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients — ACTIVE_NOT_RECRUITING · PHASE1
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep — COMPLETED · PHASE2
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma — COMPLETED · PHASE2
• Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma — COMPLETED · PHASE1
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma — COMPLETED · PHASE2
• An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — NOT_YET_RECRUITING · PHASE1
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia — COMPLETED · PHASE2
• Allo HSCT Using RIC for Hematological Diseases — COMPLETED · PHASE2
• CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — OTHER · NA
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies — COMPLETED · PHASE2
• Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation — NOT_YET_RECRUITING · PHASE2
• Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma — COMPLETED · PHASE1
• A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia — COMPLETED · PHASE1
• a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients — OTHER · NA
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia — COMPLETED · PHASE2
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia — WITHDRAWN · PHASE1
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants — COMPLETED · PHASE2
• Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen — TERMINATED · PHASE2
• Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) — OTHER · PHASE1
• Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia — OTHER · PHASE2

Refine this search